Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.

Inclusion Criteria:

• Participant must be able to understand and communicate with the investigator andcomply with the requirements of the study and must give a written, signed and datedinformed consent before any study assessment is performed.

• Chinese male or non-pregnant, non-lactating Chinese female participants at least 18years of age.

• Diagnosis of PsA classified by Classification of Psoriatic Arthritis (CASPAR)criteria and with symptoms for at least 6 months with moderate to severe Psoriaticarthritis (PsA).

• Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodiesnegative at screening.

• Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis or adocumented history of plaque psoriasis.

• Participants on Methotrexate (MTX) must be on folic acid supplementation atrandomization.

• Participants who are on a DMARD other than MTX must discontinue the DMARD 4 weeksprior to randomization visit except for leflunomide, which has to be discontinuedfor 8 weeks prior to randomization unless a cholestyramine washout has beenperformed.

Exclusion Criteria:

• Chest X-ray or chest MRI with evidence of ongoing infectious or malignant process,obtained within 3 months prior to screening and evaluated by a qualified physician

• Participants taking high potency opioid analgesics (e.g., methadone, hydromorphone,morphine).

• Previous exposure to secukinumab or other biologic drug directly targetinginterleukin- 17 (IL-17) or IL-17 receptor

• Participants who have ever received biologic immunomodulating agents except forthose targeting Tumor necrosis factor alpha (TNFα).

• Women of child-bearing potential, defined as all women physiologically capable ofbecoming pregnant, unless they are using effective contraception during the entirestudy (during the entire study).